---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Loncastuximab Tesirine-lpyl - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/loncastuximabtesirine-lpyl
version: v1
---

# Loncastuximab Tesirine-lpyl - NCI

# Loncastuximab Tesirine-lpyl

Placeholder slot

(LON-kas-TUK-sih-mab TEH-sih-reen)

This page contains brief information about loncastuximab tesirine-lpyl
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Zynlonta

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af54af12-3edf-4301-8bc5-0446bc813c1d&audience=consumer)

## Use in Cancer

Loncastuximab tesirine-lpyl
is approved to treat:

- **[B-cell](/Common/PopUps/popDefinition.aspx?id=444967&version=Patient&language=English) [non-Hodgkin lymphoma](/Common/PopUps/popDefinition.aspx?id=45148&version=Patient&language=English)** (NHL), including the following types:
- [Diffuse large B-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=428286&version=Patient&language=English) (DLBCL).
- DLBCL in patients who had [low-grade lymphoma](/Common/PopUps/popDefinition.aspx?id=45757&version=Patient&language=English).
- [High-grade](/Common/PopUps/popDefinition.aspx?id=45710&version=Patient&language=English) B-cell lymphoma.

It is used in adults whose [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=Patient&language=English) has [relapsed](/Common/PopUps/popDefinition.aspx?id=45866&version=Patient&language=English) (come back) or has not gotten better after at least two types of [systemic therapy](/Common/PopUps/popDefinition.aspx?id=45922&version=Patient&language=English).

Loncastuximab tesirine-lpyl is approved under FDAâ€™s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that it provides a clinical benefit in these patients.

Loncastuximab tesirine-lpyl
is also being studied in the treatment of other types of
cancer.

## More About Loncastuximab Tesirine-lpyl

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/778954) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Loncastuximab Tesirine-lpyl](https://medlineplus.gov/druginfo/meds/a621031.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Cancer Therapies](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Loncastuximab Tesirine-lpyl](https://www.cancer.gov/research/participate/clinical-trials/intervention/C125549) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
